Patents by Inventor John J. Hunter
John J. Hunter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8252915Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 46743, 27417, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 46743, 27417, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 46743, 27417, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: July 1, 2010Date of Patent: August 28, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, John J. Hunter, Fong-Ying Tsai
-
Publication number: 20110182879Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 46743, 27417, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 46743, 27417, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 46743, 27417, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: July 1, 2010Publication date: July 28, 2011Applicant: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Mark Williamson, Kevin R. Leiby, Rosana Kapeller-Libermann, Peter J. Olandt, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai, John J. Hunter
-
Patent number: 7879989Abstract: The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted.Type: GrantFiled: October 30, 2007Date of Patent: February 1, 2011Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, John J. Hunter
-
Patent number: 7776577Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 16, 2008Date of Patent: August 17, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rosanna Kapeller-Libermann, John J. Hunter
-
Patent number: 7482147Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 21, 2005Date of Patent: January 27, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John J. Hunter
-
Publication number: 20080182741Abstract: A system for folding cartons includes a carton conveyor for supporting and transporting cartons in a flow direction along a path, an active folding element, flight bars, and folding structures. A space for receiving a carton is defined by a conveying surface of the carton conveyor and support surfaces of the flight bars. The folding structures protrude into the space and are positioned to contact a carton proximate to a fold line to facilitate folding the carton with the active folding element.Type: ApplicationFiled: January 31, 2008Publication date: July 31, 2008Inventors: John J. Hunter, John W. Cash
-
Patent number: 7301016Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted.Type: GrantFiled: June 27, 2002Date of Patent: November 27, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Mark Williamson, Kevin R. Leiby, Rosana Kapeller-Libermann, Peter J. Olandt, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai, John J. Hunter
-
Publication number: 20040235071Abstract: The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 14218, 33877, 10317, 10485, 25964, 14815, 1363, 1397, 14827, 21708, 3801, 64698, 2179 and 13249 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions.Type: ApplicationFiled: December 16, 2003Publication date: November 25, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Eric S. Lightcap, Jeffrey A. Ecsedy, John J. Hunter, Kyle J. MacBeth, Michelle Tighe Nestor
-
Publication number: 20030224376Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted.Type: ApplicationFiled: June 27, 2002Publication date: December 4, 2003Inventors: Rachel E. Meyers, Mark Williamson, Kevin R. Leiby, Rosana Kapeller-Libermann, Peter J. Olandt, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai, John J. Hunter
-
Publication number: 20030162172Abstract: The present invention relates to a newly identified G-protein-coupled receptor. The invention also relates to polynucleotides encoding the receptors. The invention further relates to methods using receptor polypeptides and polynucleotides for diagnosis and treatment in receptor-mediated disorders. The invention further relates to methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists useful for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides by recombinant methods.Type: ApplicationFiled: December 18, 2000Publication date: August 28, 2003Inventors: Maria Alexandra Glucksmann, Martin R. Hodge, John J. Hunter, Laura Rudolph-Owen, Nadine S. Weich
-
Publication number: 20030129644Abstract: The present invention relates to a newly identified member of the superfamily of G-protein-coupled receptors, and a new member of the EDG receptor family. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.Type: ApplicationFiled: January 9, 2003Publication date: July 10, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Maria Alexandra Glucksmann, Nadine S. Weich, John J. Hunter
-
Publication number: 20030040474Abstract: The invention provides isolated nucleic acids molecules, designated 32229 nucleic acid molecules, which encode novel acyl-CoA dehydrogenase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32229 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32229 gene has been introduced or disrupted. The invention still further provides isolated 32229 proteins, fusion proteins, antigenic peptides and anti-32229 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: October 22, 2001Publication date: February 27, 2003Inventors: Rosana Kapeller-Libermann, John J. Hunter, Laura A. Rudolph-Owen
-
Publication number: 20030017539Abstract: The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 7, 2002Publication date: January 23, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Maria Alexandra Glucksmann, Martin R. Hodge, John J. Hunter, Laura A. Rudolph-Owen, Inmaculada Silos-Santiago, Nadine S. Weich
-
Publication number: 20020068291Abstract: The invention provides isolated nucleic acids molecules, designated 32252 nucleic acid molecules, which encode novel AMP-binding enzyme members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32252 gene has been introduced or disrupted. The invention still further provides isolated 32252 proteins, fusion proteins, antigenic peptides and anti-32252 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 15, 2001Publication date: June 6, 2002Inventors: Rachel A. Meyers, John J. Hunter
-
Publication number: 20010039331Abstract: The invention provides isolated nucleic acids molecules, designated 16836 nucleic acid molecules, which encode novel phospholipase C members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16836 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16836 gene has been introduced or disrupted. The invention still further provides isolated 16836 proteins, fusion proteins, antigenic peptides and anti-16836 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: March 30, 2001Publication date: November 8, 2001Inventors: John J. Hunter, Rachel A. Meyers
-
Patent number: 6172190Abstract: The present invention relates to the discovery and characterization of two novel forms of Caspase-8. The first Caspase-8 of the invention, Caspase-8h, encodes a 220 amino acid polypeptide which includes two FADD death effector domains. The second caspase of the invention, Caspase-8i, encodes an 81 amino acid polypeptide having one FADD death effector domain. The invention encompasses nucleic acid molecules encoding Caspase-8h and Caspase-8i, vectors containing these nucleic acid molecules, cells harboring recombinant DNA encoding Caspase-8h and/or Caspase-8i, host fusion proteins which include Caspase-8h and/or Caspase-8i, transgenic animals which express Caspase-8h and/or Caspase-8i, therapeutic methods, purified Casapase-8h, purified Casapase-8i, therapeutic compounds and methods employing Caspase-8h and Caspase-8i, and screening methods employing Caspase-8h and Caspase-8i.Type: GrantFiled: December 31, 1997Date of Patent: January 9, 2001Assignee: Millennium Pharmaceuticals, Inc.Inventors: John J. Hunter, Andrew W. Shyjan, Grace H. W. Wong
-
Patent number: 5837837Abstract: The present invention concerns the Caspase-8h gene and the Caspase-8i gene. The Caspase-8h gene encodes a 220 amino acid polypeptide having two FADD death effector domains. The Caspase-8i gene encodes an 81 amino acid polypeptide having one FADD death effector domain. The invention encompasses nucleic acid molecules encoding Caspase-8h or Caspase-8i, vectors containing these nucleic acid molecules, and cells harboring such vectors.Type: GrantFiled: February 27, 1997Date of Patent: November 17, 1998Assignee: Millennium Pharmaceuticals, Inc.Inventors: John J. Hunter, Andrew W. Shyjan, Grace H. W. Wong
-
Patent number: 4709946Abstract: Disclosed is a method and apparatus for forming a pipe joint for securing lined pipe sections together. A portion of the liners of adjacent pipe sections are overlapped and compressed when the pipe joint is made up so as to seal against the migration of pressurized fluids from within the pipe sections.Type: GrantFiled: February 20, 1987Date of Patent: December 1, 1987Inventor: John J. Hunter
-
Patent number: 4541655Abstract: Disclosed is a pipe coupling joint comprising an interference fit coupling of unthreaded pipe sections. The end of the outer pipe in a telescoped interference fit coupling is radially compressed to form a groove in the inner pipe. The crimped end is compressed into the groove to securely couple the pipe sections together. Lined pipe joints and methods and apparatus for forming the improved interference fit joint are also disclosed.Type: GrantFiled: February 7, 1983Date of Patent: September 17, 1985Inventor: John J. Hunter
-
Patent number: 4418458Abstract: Disclosed is a pipe coupling joint comprising an interference fit coupling of unthreaded pipe sections. The end of the outer pipe in a telescoped interference fit coupling is radially compressed to form a groove in the inner pipe. The crimped end is compressed into the groove to securely couple the pipe sections together. Lined pipe joints and methods and apparatus for forming the improved interference fit joint are also disclosed.Type: GrantFiled: November 18, 1980Date of Patent: December 6, 1983Inventor: John J. Hunter